BRIEF published on 06/17/2024 at 07:05, 5 months 4 days ago Innate Pharma dévoile des résultats prometteurs pour le SAR443579/IPH6101 dans des cancers du sang Sanofi Innate Pharma SAR443579 Leucémie Cancer Du Sang
PRESS RELEASE published on 06/17/2024 at 07:00, 5 months 4 days ago Informations privilégiées / Autres communiqués Innate Pharma présente de nouveaux résultats sur l'essai de phase 1/2 mené par Sanofi évaluant le NK Cell Engager SAR443579/IPH6101 dans divers cancers du sang lors du congrès annuel de l'EHA 2024 Étude De Phase 1/2 Innate Pharma NK Cell Engager SAR443579/IPH6101 Cancers Du Sang
PRESS RELEASE published on 06/17/2024 at 07:00, 5 months 4 days ago Inside Information / Other news releases Innate Pharma shares updated results from the Sanofi developed blood cancer Phase 1/2 SAR443579/IPH6101 trial, showing promising clinical efficacy and safety in patients with R/R AML Sanofi Innate Pharma Blood Cancer NK Cell Engager Phase 1/2 Trial
BRIEF published on 05/28/2024 at 07:05, 5 months 24 days ago Innate Pharma announces its participation in upcoming investor conferences Biotechnology Investor Conferences Immunotherapy Health Innate Pharma
BRIEF published on 05/28/2024 at 07:05, 5 months 24 days ago Innate Pharma annonce sa participation à de prochaines conférences investisseurs Immunothérapie Santé Conférences Investisseurs Innate Pharma Biotechnologies
PRESS RELEASE published on 05/28/2024 at 07:00, 5 months 24 days ago Informations privilégiées / Autres communiqués Innate Pharma annonce sa participation à des conférences investisseurs mondiales à venir. Détails des conférences et objectif de la société biotechnologique axée sur les immunothérapies contre le cancer Biotechnologie Immunothérapie Cancer Conférences Investisseurs Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 5 months 28 days ago Results of the Combined General Meeting of Innate Pharma Voting Results Supervisory Board General Assembly Innate Pharma
BRIEF published on 05/23/2024 at 22:05, 5 months 28 days ago Résultats de l'Assemblée Générale Mixte d'Innate Pharma Assemblée Générale Conseil De Surveillance Innate Pharma Résultats De Vote
PRESS RELEASE published on 05/23/2024 at 22:00, 5 months 28 days ago Inside Information / Other news releases Innate Pharma announces the voting results of its 2024 AGM. Quorum at 44.92%. Re-election of two Supervisory Board members. Details available on company's website Voting Results Supervisory Board Quorum 2024 AGM Innate Pharma
PRESS RELEASE published on 05/23/2024 at 22:00, 5 months 28 days ago Informations privilégiées / Autres communiqués Innate Pharma annonce les résultats de l'Assemblée générale mixte du 23 mai 2024 avec réélection des membres du Conseil de Surveillance. Détails disponibles en ligne Résultats Conseil De Surveillance Assemblée Générale Mixte Innate Pharma Biotechnologies
Published on 11/21/2024 at 11:30, 30 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 1 hour 57 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 09:00, 3 hours ago ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 11 hours 25 minutes ago Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 11:30, 30 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 11:01, 59 minutes ago Original-Research: SMT Scharf AG (von Montega AG): Kaufen
Published on 11/21/2024 at 11:00, 1 hour ago First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach
Published on 11/21/2024 at 10:56, 1 hour 3 minutes ago ABO Energy closes sale for two Battery Projects in South Africa
Published on 11/21/2024 at 10:30, 1 hour 30 minutes ago MS Industrie AG publishes unaudited key figures for the first 3 quarters 2024
Published on 11/21/2024 at 06:58, 5 hours 2 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 2 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 5 hours 2 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 15 hours 52 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 16 hours 40 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
